Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BeiGene Ltd ( (HK:6160) ) has provided an announcement.
BeOne Medicines Ltd., a company incorporated in Switzerland, has issued an overseas regulatory announcement regarding its Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarterly period ended September 30, 2025. The announcement highlights the company’s compliance with reporting requirements and provides details on its securities registered on The Nasdaq Global Select Market and The Stock Exchange of Hong Kong Limited. This filing underscores BeOne Medicines’ commitment to transparency and regulatory adherence, potentially reinforcing its credibility and stability in the market.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 5,386,090
Technical Sentiment Signal: Buy
Current Market Cap: HK$275.5B
Learn more about 6160 stock on TipRanks’ Stock Analysis page.